Drug Profile


Alternative Names: CMI CSX-1A; CMI X-11A; DCA I.V.

Latest Information Update: 19 Aug 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Alberta
  • Developer Valens Pharma
  • Class Acetates; Adjunct therapies; Cardiovascular therapies; Chlorinated hydrocarbons
  • Mechanism of Action Pyruvate dehydrogenase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Reperfusion injury

Most Recent Events

  • 19 Aug 2008 qc
  • 05 Aug 2008 Suspended - Phase-II for Reperfusion injury in Canada (IV)
  • 28 Jul 2008 Valens Pharma completes phase II trial in reperfusion injury in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top